Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/TEVA PHARMACEUTICAL INDUSTRIES LTD/ 10-Q

Quarterly Report · 10-Q

TEVA PHARMACEUTICAL INDUSTRIES LTD

Quarterly Report

Filed Apr 29, 2026Accepted Apr 29, 2026, 4:06 PM EDTCIK 818686Accession 0001193125-26-191513
View company →Permanent SEC source ↗
Share

Company context

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health.

Current securities

TEVANYSE · ADR · Current
Historical securities (1)
TEVJFOTC · UNIT · Historical · closed Sep 14, 2026

Recent company filings

  1. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsOct 29, 2026
  2. 144 filingSep 21, 2026
  3. 144 filingSep 18, 2026
  4. Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet ArrangementSep 16, 2026
  5. Other EventsSep 14, 2026

Registered securities in this filing

TEVA PHARMACEUTICAL INDUSTRIES LIMITED · 10-Q · Filed 2026-04-29

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

American Depositary Shares, each representing one Ordinary Share

Symbol
TEVA
Exchange
NYSE
Classification
ADS
Status
Current
Filing context

Context: P01_01_2026To03_31_2026

Dimensions: Not supplied

Accession 000119312526191513 · 1 registered-security cover member

Read the exact SEC filing ↗

As-filed source

Primary evidence
As filedOpen full document ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.